Ftse Mib
34.890,11
0,46%
DAX
20.433,43
0,10%
S&P 500
6.084,19
0,00%
NASDAQ
20.034,89
0,00%
Bitcoin
101.479,70
0,28%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aldeyra Therapeutics Inc (ALDX) Aldeyra Therapeutics Inc (ALDX) Notizie

Aldeyra Therapeutics Inc

ALDX
5,59
0,22 (4,10%)
Pre Mercato
Ultimo aggiornamento: 14:43:12
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/12/202413:00BWAldeyra Therapeutics to Participate in the Citi 2024 Global..
18/11/202413:01EDGAR2Form 8-K - Current report
18/11/202413:00BWAldeyra Therapeutics Announces FDA Acceptance for Review of..
14/11/202413:00BWAldeyra Therapeutics to Participate in the Jefferies London..
07/11/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202412:00BWAldeyra Therapeutics Selected to Present at the Disruptive..
22/10/202402:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202413:01EDGAR2Form 8-K - Current report
03/10/202413:00BWAldeyra Therapeutics Resubmits Reproxalap New Drug..
02/10/202422:10EDGAR2Form 8-K - Current report
10/9/202422:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202413:00BWAldeyra Therapeutics to Participate in the H.C. Wainwright..
03/9/202415:02EDGAR2Form 8-K - Current report
14/8/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/8/202400:07EDGAR2Form 144 - Report of proposed sale of securities
12/8/202423:45EDGAR2Form 144 - Report of proposed sale of securities
08/8/202413:06EDGAR2Form 8-K - Current report
08/8/202413:00BWAldeyra Therapeutics Achieves Primary Endpoint in Phase 3..
07/8/202422:01BWAldeyra Therapeutics Schedules Conference Call and Webcast..
01/8/202423:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/8/202422:11EDGAR2Form 8-K - Current report
01/8/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
20/6/202413:01EDGAR2Form 8-K - Current report
20/6/202413:00BWAldeyra Therapeutics Announces Advancement of New RASP..
13/6/202413:01EDGAR2Form 8-K - Current report
13/6/202413:00BWAldeyra Therapeutics Completes Enrollment in Phase 3..
12/6/202413:00BWAldeyra Therapeutics to Host Investor Roundtable Q&A
07/6/202422:07EDGAR2Form 8-K - Current report
06/6/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202413:00BWAldeyra Therapeutics to Participate in the Jefferies Global..
08/5/202413:00BWAldeyra Therapeutics Enrolls First Patient in Phase 3..
25/4/202413:00BWAldeyra Therapeutics Highlights Recent Preclinical Data in..
18/4/202413:00BWAldeyra Therapeutics to Host Research & Development Day on..
28/3/202412:00BWAldeyra Therapeutics Announces Clinical Development Plan for..
07/3/202422:54EDGAR2Form S-3 - Registration statement under Securities Act of..
07/3/202422:48EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202422:40EDGAR2Form S-8 POS - Securities to be offered to employees in..
07/3/202422:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/2/202413:00BWAldeyra Therapeutics to Participate in the Oppenheimer 34th..
29/1/202423:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
04/1/202413:00EDGAR2Form 8-K - Current report
04/1/202413:00BWAldeyra Therapeutics Provides Clinical and Regulatory Update..
21/12/202322:06EDGAR2Form 8-K - Current report
19/12/202313:05EDGAR2Form 8-K - Current report
19/12/202313:00BWAldeyra Therapeutics Announces Statistically and Clinically..
18/12/202322:01BWAldeyra Therapeutics Schedules Conference Call and Webcast..
Apertura: Min: Max:
Chiusura: 5,37

La tua Cronologia

NASDAQ
ALDX
Aldeyra Therapeutics
BIT
TWL
TraWell
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network